Neuronal nicotinic acetylcholine receptors: Structural revelations, target identifications, and therapeutic inspirations

Journal of Medicinal Chemistry

Volumn 48, Issue 15, 2005, Pages 4705-4745

  Jensen, Anders A ^a   Frølund, Bente ^a   Liljefors, Tommy ^a   Krogsgaard Larsen, Povl ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; 5 IODO 3 (2 AZETIDINYLMETHOXY)PYRIDINE; ACETYLCHOLINE; ALTINICLIN; BINDING PROTEIN; CHROMAPERIDINE; CHROMAPROLINE; CYSTINE; EPIBATIDINE; ISPRONICLINE; NEURONAL NICOTINIC RECEPTOR; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; QUINUCLIDINE; RECEPTOR SUBTYPE; SIB 1469; SIB 1663; SSR 591813; TC 1827; TC 2043; TC 2403; TC 2429; TC 2559; TEBANICLINE; TROPANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; CARDIOTOXICITY; CHANNEL GATING; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; EPILEPSY; GASTROINTESTINAL SYMPTOM; HUMAN; ION CHANNEL DOMAIN; ION CONDUCTANCE; MEMORY DISORDER; MODEL; MOLECULAR CLONING; MOTOR DYSFUNCTION; NONHUMAN; PAIN; PARKINSON DISEASE; PHYSIOLOGY; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE BASED DESIGN; THERAPY; TISSUE DISTRIBUTION; ULCERATIVE COLITIS; WITHDRAWAL SYNDROME;

ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; ANIMALS; HUMANS; LIGANDS; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PROTEIN CONFORMATION; PROTEIN SUBUNITS; RECEPTORS, NICOTINIC;

EID: 22844432580     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040219e     Document Type: Review

References (268)

1. Lee, C. Conformation, action, and mechanism of action of neuromuscular blocking muscle relaxants. Pharmacol. Ther. 2003, 98, 143-169.
2. Arneric, S. P., Brioni, J. D., Eds. Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities; Wiley-Liss, Inc.: New York, 1999.
3. Paterson, D.; Nordberg, A. Neuronal nicotinic receptors in the human brain. Prog. Neurobiol. 2000, 61, 75-111.
4. Levin, E. D., Ed. Nicotinic Receptors in the Nervous System; CRC Press: Boca Raton, FL, 2002.
5. Sher, E.; Chen, Y.; Sharples, T. J.; Broad, L. M.; Benedetti, G.; Zwart, R.; McPhie, G. I.; Pearson, K. H.; Baldwinson, T.; De Filippi, G. Physiological roles of neuronal nicotinic receptor subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity. Curr. Top. Med. Chem. 2004, 4, 283-297.
6. Lukas, R. J.; Changeux, J. P.; Le Novere, N.; Albuquerque, E. X.; Balfour, D. J.; Berg, D. K.; Bertrand, D.; Chiappinelli, V. A.; Clarke, P. B.; Collins, A. C.; Dani, J. A.; Grady, S. R.; Kellar, K. J.; Lindstrom, J. M.; Marks, M. J.; Quik, M.; Taylor, P. W.; Wonnacott, S. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev. 1999, 51, 397-401.
7. Wonnacott, S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997, 20, 92-98.
8. Newhouse, P.; Singh, A.; Potter, A. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Curr. Top. Med. Chem. 2004, 4, 267-282.
9. Ripoll, N.; Bronnec, M.; Bourin, M. Nicotinic receptors and schizophrenia. Curr. Med. Res. Opin. 2004, 20, 1057-1074.
10. Shytle, R. D.; Silver, A. A.; Lukas, R. J.; Newman, M. B.; Sheehan, D. V.; Sanberg, P. R. Nicotinic acetylcholine receptors as targets for antidepressants. Mol. Psychiatry 2002, 7, 525-535.
11. Corringer, P.-J.; Le Novère, N.; Changeux, J.-P. Nicotinic receptors at the amino acid level. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 431-458.
12. Karlin, A. Emerging structure of the nicotinic acetylcholine receptors. Nat. Rev. Neurosci. 2002, 3, 102-114.
13. Sieghart, W.; Sperk, G. Subunit composition, distribution and function of GABAA receptor subtypes. Curr. Top. Med. Chem. 2002, 2, 795-816.
14. Lynch, J. W. Molecular structure and function of the glycine receptor chloride channel. Physiol. Rev. 2004, 84, 1051-1095.
15. Nelson, M. E.; Kuryatov, A.; Choi, C. H.; Zhou, Y.; Lindstrom, J. Alternate stoichiometries of α4β2 nicotinic acetylcholine receptors. Mol. Pharmacol. 2003, 63, 332-341.
16. Stauderman, K. A.; Mahafy, L. S.; Akong, M.; Velicelebi, G.; Chavez-Noriega, L. E.; Crona, J. H.; Johnson, E. C.; Elliott, K. J.; Gillespie, A.; Reid, R. T.; Adams, P.; Harpold, M. M.; Corey-Naeve, J. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations α2β4, α3β4, and α4β4 stably expressed in HEK293 cells. J. Pharmacol. Exp. Ther. 1998, 284, 777-789.
17. Chavez-Noriega, L. E.; Crona, J. H.; Washburn, M. S.; Urrutia, A.; Elliott, K. J.; Johnson, E. C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4, and hα7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997, 280, 346-356.
18. Chavez-Noriega, L. E.; Gillespie, A.; Stauderman, K. A.; Crona, J. H.; Claeps, B. O.; Elliott, K. J.; Reid, R. T.; Rao, T. S.; Velicelebi, G.; Harpold, M. M.; Johnson, E. C.; Corey-Naeve, J. Characterization of the recombinant human neuronal nicotinic acetylcholine receptors α3β2 and α4β2 stably expressed in HEK293 cells. Neuropharmacology 2000, 39, 2543-2560.
19. Kuryatov, A.; Olale, F.; Cooper, J.; Choi, C.; Lindstrom, J. Human α6 AChR subtypes: subunit composition, assembly, and pharmacological responses. Neuropharmacology 2000, 39, 2570-2590.
20. Dowell, C.; Olivera, B. M.; Garrett, J. E.; Staheli, S. T.; Watkins, M.; Kuryatov, A.; Yoshikami, D.; Lindstrom, J. M.; McIntosh, J. M. α-Conotoxin PIA is selective for α6-containing nicotinic acetylcholine receptors. J. Neurosci. 2003, 23, 8445-8452.
21. Ramirez-Latorre, J.; Yu, C. R.; Qu, X.; Perin, F.; Karlin, A.; Role, L. Functional contributions of α5 subunit to neuronal acetylcholine receptor channels. Nature 1996, 380, 347-351.
22. Boorman, J. P.; Beato, M.; Groot-Kormelink, P. J.; Broadbent, S. D.; Sivilotti, L. G. The effects of β3 subunit incorporation of the pharmacology and single channel properties of oocyte-expressed human α3β4 neuronal nicotinic receptors. J. Biol. Chem. 2003, 278, 44033-44040.
23. 2+ modulation of human α3 nicotinic receptors. J. Pharmacol. Exp. Ther. 1998, 286, 311-320.
24. Grinevich, V. P.; Letchworth, S. R.; Lindenberger, K. A.; Menager, J.; Mary, V.; Sadieva, K. A.; Buhlman, L.; Bohme, G. A.; Pradier, L.; Benavides, J.; Lukas, R. J.; Bencherif, M. Heterologous expression of human α6β4β3α5 nicotinic acetylcholine receptors: binding properties consistent with their natural expression require quaternary subunit assembly including the α5 subunit. J. Pharmacol. Exp. Ther. 2005, 372, 619-626.
25. Palma, E.; Maggi, L.; Barabino, B.; Eusebi, F.; Ballivet, M. Nicotinic acetylcholine receptors assembled from the α7 and β3 subunits. J. Biol. Chem. 1999, 274, 18335-18340.
26. Khiroug, S. S.; Harkness, P. C.; Lamb, P. W.; Sudweeks, S. N.; Khiroug, L.; Millar, N. S.; Yakel, J. L. Rat nicotinic ACh receptor α7 and β2 subunits co-assemble to form functional heteromeric nicotinic receptor channels. J. Physiol. 2002, 540, 425-434.
27. 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994, 79, 705-715.
28. Elgoyhen, A. B.; Vetter, D. E.; Katz, E.; Rothlin, C. V.; Heinemann, S. F.; Boulter, J. α10: A determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3501-3506.
29. Wada, E.; Wada, K.; Boulter, J.; Deneris, E.; Heinemann, S.; Patrick, J.; Swanson, L. W. Distribution of α2, α3, α4, and β2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J. Comp. Neurol. 1989, 284, 314-335.
30. Sargent, P. B. The distribution of neuronal nicotinic acetylcholine receptors. In Neuronal Nicotinic Receptors; Clementi, F., Fornasari, D., Gotti, C., Eds.; Handbook of Experimental Pharmacology, Vol. 144; Springer: Berlin, 2000; pp 163-184.
31. Quik, M.; Polonskaya, Y.; Gillespie, A.; Jakowec, M.; Lloyd, G. K.; Langston, J. W. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. J. Comp. Neurol. 2000, 425, 58-69.
32. Quik, M.; Vailati, S.; Bordia, T.; Kulak, J. M.; Fan, H.; McIntosh, J. M.; Clementi, F.; Gotti, C. Subunit composition of nicotinic receptors in monkey striatum; effect of MPTP and L-dopa treatments. Mol. Pharmacol. 2005, 67, 32-41.
33. Picciotto, M. R.; Caldarone, B. J.; Brunzell, D. H.; Zachariou, V.; Stevens, T. R.; King, S. L. Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol. Ther. 2001, 92, 89-108.
34. Cui, C.; Booker, T. K.; Allen, R. S.; Grady, S. R.; Whiteaker, P.; Marks, M. J.; Salminen, O.; Tritto, T.; Butt, C. M.; Allen, W. R.; Stitzel, J. A.; McIntosh, J. M.; Boulter, J.; Collins, A. C.; Heinemann, S. F. The β3 nicotinic receptor subunit: a component of α-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. J. Neurosci. 2003, 23, 11045-11053.
35. Conroy, W. G.; Berg, D. K. Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J. Biol. Chem. 1995, 270, 4424-4431.
36. Vernallis, A. B.; Conroy, W. G.; Berg, D. K. Neurons assemble acetylcholine receptors with as many as three kinds of subunits while maintaining subunit segregation among receptor subtypes. Neuron 1993, 10, 451-464.
37. Zoli, M.; Léna, C.; Picciotto, M. R.; Changeux, J.-P. Identification of four classes of brain nicotinic receptors using β2 mutant mice. J. Neurosci. 1998, 18, 4461-4472.
38. Klink, R.; de Kerchove d'Exaerde, A.; Zoli, M.; Changeux, J. P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J. Neurosci. 2001, 27, 1452-1463.
39. Kulak, J. M.; Nguyen, T. A.; Olivera, B. M.; McIntosh, J. M. α-Conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. J. Neurosci. 1997, 17, 5263-5270.
40. 3H]dopamine release from rat striatal synaptosomes and slices. J. Neurochem. 1998, 70, 1069-1076.
41. Luo, S.; Kulak, J. M.; Cartier, G. E.; Jacobsen, R. B.; Yoshikami, D.; Olivera, B. M.; McIntosh, J. M. α-Conotoxin AuIB selectively blocks α3β4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. J. Neurosci. 1998, 18, 8571-8579.
42. Sharples, C. G. V.; Kaiser, S.; Soliakov, L.; Marks, M. J.; Collins, A. C.; Washburn, M. S.; Wright, E.; Spencer, J. A.; Gallagher, T.; Whiteaker, P.; Wonnacott, S. UB-165: A novel nicotinic agonist with subtype selectivity implicates the α4β2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J. Neurosci. 2000, 20, 2783-2791.
43. Champtiaux, N.; Han, Z. Y.; Bessis, A.; Rossi, F. M.; Zoli, M.; Marubio, L.; McIntosh, J. M.; Changeux, J. P. Distribution and pharmacology of α6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J. Neurosci. 2002, 22, 1208-1217.
44. Whiteaker, P.; Peterson, C. G.; Xu, W.; McIntosh, J. M.; Paylor, R.; Beaudet, A. L.; Collins, A. C.; Marks, M. J. Involvement of the α3 subunit in central nicotinic binding populations. J. Neurosci. 2002, 22, 2522-2529.
45. Salminen, O.; Murphy, K. L.; McIntosh, J. M.; Drago, J.; Marks, M. J.; Collins, A. C.; Grady, S. R. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 2004, 65, 1526-1535.
46. Champtiaux, N.; Gotti, C.; Cordero-Erausquin, M.; David, D. J.; Przybylski, C.; Lena, C.; Clementi, F.; Moretti, M.; Rossi, F. M.; Le Novere, N.; McIntosh, J. M.; Gardier, A. M.; Changeux, J. P. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci. 2003, 23, 7820-7829.
47. 3H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 2000, 58, 312-318.
48. Mansvelder, H. D.; Keath, J. R.; McGehee, D. S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 2002, 33, 905-919.
49. Champtiaux, N.; Changeux, J.-P. Knock-out and knock-in mice to investigate the role of nicotinic receptors and the central nervous system. Curr. Drug. Targets: CNS Neurol. Disord. 2002, 1, 319-330.
50. Xu, W.; Gelber, S.; Orr-Urtreger, A.; Armstrong, D.; Lewis, R. A.; Ou, C. N.; Patrick, J.; Role, L.; De Biasi, M.; Beaudet, A. L. Megacystis, mydriasis, and ion channel defect in mice lacking the α3 neuronal nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 5746-5751.
51. Xu, W.; Orr-Urtreger, A.; Nigro, F.; Gelber, S.; Sutcliffe, C. B.; Armstrong, D.; Patrick, J. W.; Role, L. W.; Beaudet, A. L.; De Biasi, M. Multiorgan autonomic dysfunction in mice lacking the β2 and the β4 subunits of neuronal nicotinic acetylcholine receptors. J. Neurosci. 1999, 19, 9298-9305.
52. Wang, N.; Orr-Urtreger, A.; Chapman, J.; Rabinowitz, R.; Korczyn, A. D. Deficiency of nicotinic acetylcholine receptor β4 subunit causes autonomic cardiac and intestinal dysfunction. Mol. Pharmacol. 2003, 63, 574-580.
53. Salas, R.; Orr-Urtreger, A.; Broide, R. S.; Beaudet, A.; Paylor, R.; De Biasi, M. The nicotinic acetylcholine receptor subunit α5 mediates short-term effects of nicotine in vivo. Mol. Pharmacol. 2003, 63, 1059-1066.
54. Kedmi, M.; Beaudet, A. L.; Orr-Urtreger, A. Mice lacking neuronal nicotinic acetylcholine receptor β4-subunit and mice lacking both α5- and β4-subunits are highly resistant to nicotine-induced seizures. Physiol. Genomics 2004, 17, 221-229.
55. Salas, R.; Pieri, F.; De Biasi, M. Decreased signs of nicotine withdrawal in mice null for the β4 nicotinic acetylcholine receptor subunit. J. Neurosci. 2004, 24, 10035-10039.
56. Marubio, L. M.; del Mar Arroyo-Jimenez, M.; Cordero-Erausquin, M.; Lena, C.; Le Novere, N.; de Kerchove d'Exaerde, A.; Huchet, M.; Damaj, M. I.; Changeux, J. P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 1999, 398, 805-810.
57. Ross, S. A.; Wong, J. Y.; Clifford, J. J.; Kinsella, A.; Massalas, J. S.; Horne, M. K.; Scheffer, I. E.; Kola, I.; Waddington, J. L.; Berkovic, S. F.; Drago, J. Phenotypic characterization of an α4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J. Neurosci. 2000, 20, 6431-6441.
58. Picciotto, M. R.; Zoli, M.; Lena, C.; Bessis, A.; Lallemand, Y.; Le Novere, N.; Vincent, P.; Pich, E. M.; Brulet, P.; Changeux, J. P. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995, 374, 65-67.
59. Zoli, M.; Picciotto, M. R.; Ferrari, R.; Cocchi, D.; Changeux, J. P. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J. 1999, 18, 1235-1244.
60. Jain, K. K. Modulators of nicotinic acetylcholine receptors as analgesics. Curr. Opin. Invest. Drugs 2004, 5, 76-81.
61. Labarca, C.; Schwarz, J.; Deshpande, P.; Schwarz, S.; Nowak, M. W.; Fonck, C.; Nashmi, R.; Kofuji, P.; Dang, H.; Shi, W.; Fidan, M.; Khakh, B. S.; Chen, Z.; Bowers, B. J.; Boulter, J.; Wehner, J. M.; Lester, H. A. Point mutant mice with hypersensitive α4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 2786-2791.
62. Fonck, C.; Nashmi, R.; Deshpande, P.; Damaj, M. I.; Marks, M. J.; Riedel, A.; Schwarz, J.; Collins, A. C.; Labarca, C.; Lester, H. A. Increased sensitivity to agonist-induced seizures, straub tail, and hippocampal theta rhythm in knock-in mice carrying hypersensitive α4 nicotinic receptors. J. Neurosci. 2003, 23, 2582-2590.
63. Orb, S.; Wieacker, J.; Labarca, C.; Fonck, C.; Lester, H. A.; Schwarz, J. Knockin mice with Leu9′Ser α4-nicotinic receptors: substantia nigra dopaminergic neurons are hypersensitive to agonist and lost postnatally. Physiol. Genomics 2004, 18, 299-307.
64. Tapper, A. R.; McKinney, S. L.; Nashmi, R.; Schwarz, J.; Deshpande, P.; Labarca, C.; Whiteaker, P.; Marks, M. J.; Collins, A. C.; Lester, H. A. Nicotine activation of α4* receptors: sufficient for reward, rolerance, and sensitization. Science 2004, 306, 1029-1032.
65. Picciotto, M. R.; Zoli, M.; Rimondini, R.; Lena, C.; Marubio, L. M.; Pich, E. M.; Fuxe, K.; Changeux, J. P. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391, 173-177.
66. Picciotto, M. R.; Zoli, M.; Zachariou, V.; Changeux, J. P. Contribution of nicotinic acetylcholine receptors containing the beta 2-subunit to the behavioural effects of nicotine. Biochem. Soc. Trans. 1997, 25, 824-829.
67. Orr-Urtreger, A.; Goldner, F. M.; Saeki, M.; Lorenzo, I.; Goldberg, L.; De Biasi, M.; Dani, J. A.; Patrick, J. W.; Beaudet, A. L. Mice deficient in the α7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J. Neurosci. 1997, 17, 9165-9171.
68. Orr-Urtreger, A.; Broide, R. S.; Kasten, M. R.; Dang, H.; Dani, J. A.; Beaudet, A. L.; Patrick, J. W. Mice homozygous for the L250T mutation in the α7 nicotinic acetylcholine receptor show increased neuronal apoptosis and die within 1 day of birth. J. Neurochem. 2000, 74, 2154-2166.
69. Tronche, F.; Casanova, E.; Turiault, M.; Sahly, I.; Kellendonk, C. When reverse genetics meets physiology: the use of site-specific recombinases in mice. FEBS Lett. 2002, 529, 116-121.
70. Brejc, K.; van Dijk, W. J.; Klaassen, R. V.; Schuurmans, M.; van Der Oost, J.; Smit, A. B.; Sixma, T. K. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001, 411, 269-276.
71. Celie, P. H.; van Rossum-Fikkert, S. E.; van Dijk, W. J.; Brejc, K.; Smit, A. B.; Sixma, T. K. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 2004, 41, 907-917.
72. Miyazawa, A.; Fujiyoshi, Y.; Unwin, N. Structure and gating mechanism of the acetylcholine receptor pore. Nature 2003, 423, 949-956.
73. Monod, J.; Wyman, J.; Changeux, J.-P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 1965, 12, 88-118.
74. Changeux, J.-P.; Edelstein, S. J. Allosteric receptors after 30 years. Neuron 1998, 21, 959-980.
75. Jackson, M. B. Spontaneous openings of the acetylcholine receptor channel. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 3901-3904.
76. Unwin, N.; Toyoshima, C.; Kubalek, E. Arrangement of the acetylcholine receptor subunits in the resting and desensitized states, determined by cryoelectron microscopy of crystallized Torpedo postsynaptic membranes. J. Cell Biol. 1988, 107, 1123-1138.
77. Unwin, N. Nicotinic acetylcholine receptor at 9 Å resolution. J. Mol. Biol. 1993, 229, 1101-1124.
78. Unwin, N. Acetylcholine receptor channel imaged in the open state. Nature 1995, 373, 37-43.
79. Unwin, N. Projection structure of the nicotinic acetylcholine receptor: distinct conformations of the α subunits. J. Mol. Biol. 1996, 257, 586-596.
80. Miyazawa, A.; Fujiyoshi, Y.; Stowell, M.; Unwin, N. Nicotinic acetylcholine receptor at 4.6 Å resolution: transverse tunnels in the channel wall. J. Mol. Biol. 1999, 288, 765-786.
81. Unwin, N.; Miyazawa, A.; Li, J.; Fujiyoshi, Y. Activation of the nicotinic acetylcholine receptor involves a switch in conformation of the α subunits. J. Mol. Biol. 2002, 379, 1165-1176.
82. Keramidas, A.; Moorhouse, A. J.; Schofield, P. R.; Barry, P. H. Ligand-gated ion channels: mechanisms underlying ion selectivity. Prog. Biophys. Mol. Biol. 2004, 86, 161-204.
83. Galzi, J.-L.; Devillers-Thiéry, A.; Hussy, N.; Bertrand, S.; Changeux, J.-P.; Bertrand, D. Mutations in the channel domain of a neuronal nicotinic receptor convert ion selectivity from cationic to anionic. Nature 1992, 359, 500-505.
84. Keramidas, A.; Moorhouse, A. J.; Pierce, K. D.; Schofield, P. R.; Barry, P. H. Cation-selective mutations in the M2 domain of the inhibitory glycine receptor channel reveal determinants of ion-charge selectivity. J. Gen. Physiol. 2002, 119, 393-410.
85. Bertrand, D.; Galzi, J.-L.; Devillers-Thiéry, A.; Bertrand, S.; Changeux, J.-P. Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal α7 nicotinic receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6971-6975.
86. Corringer, P. J.; Bertrand, S.; Galzi, J. L.; Devillers-Thiery, A.; Changeux, J.-P.; Bertrand, D. Mutational analysis of the charge selectivity filter of the α7 nicotinic acetylcholine receptor. Neuron 1999, 22, 831-843.
87. A receptor. J. Biol. Chem. 2002, 277, 41438-41447.
88. Wilson, G. G.; Karlin, A. The location of the gate in the acetylcholine receptor channel. Neuron 1998, 20, 1269-1281.
89. Unwin, N. Structure and action of the nicotinic acetylcholine receptor explored by electron microscopy. FEBS Lett. 2003, 555, 91-95.
90. Auerbach, A.; Akk, G. Desensitization of mouse nicotinic acetylcholine receptor channels. A two-gate mechanism. J. Gen. Physiol. 1998, 112, 181-197.
91. Wilson, G.; Karlin, A. Acetylcholine receptor channel structure in the resting, open, and desensitized states probed with the substituted-cysteine- accessibility method. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 1241-1248.
92. Smit, A. B.; Syed, N. I.; Schaap, D.; van Minnen, J.; Klumperman, J.; Kits, K. S.; Lodder, H.; van der Schors, R. C.; van Elk, R.; Sorgedrager, B.; Brejc, K.; Sixma, T. K.; Geraerts, W. P. A glia-derived acetylcholine-binding protein that modulates synaptic transmission. Nature 2001, 411, 261-268.
93. Smit, A. B.; Brejc, K.; Syed, N.; Sixma, T. K. Structure and function of AChBP, homologue of the ligand-binding domain of the nicotinic acetylcholine receptor. Ann. N. Y. Acad. Sci. 2003, 998, 81-92.
94. Lester, H. A.; Dibas, M. I.; Dahan, D. S.; Leite, J. F.; Dougherty, D. A. Cys-loop receptors: new twists and turns. Trends Neurosci. 2004, 27, 329-336.
95. Zhong, W.; Gallivan, J. P.; Zhang, Y.; Li, L.; Lester, H. A.; Dougherty, D. A. From ab initio quantum mechanics to molecular neurobiology: A cation-π binding site in the nicotinic receptor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12088-12093.
96. Eiselé, J.-L.; Bertrand, S.; Galzi, J.-L.; Devillers- Thiéry, A.; Changeux, J.-P.; Bertrand, D. Chimaeric nicotinic- serotonergic receptor combines distinct ligand binding and channel specificities. Nature 1993, 366, 479-483.
97. Mihic, S. J.; Ye, Q.; Wick, M. J.; Koltchine, V. V.; Krasowski, M. D.; Finn, S. E.; Mascia, M. P.; Valenzuela, C. F.; Hanson, K. K.; Greenblatt, E. P.; Harris, R. A.; Harrison, N. L. Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature 1997, 389, 385-389.
98. Wagner, D. A.; Czajkowski, C. Structure and dynamics of the GABA binding pocket: A narrowing cleft that constricts during activation. J. Neurosci. 2001, 21, 67-74.
99. Absalom, N. L.; Lewis, T. M.; Schofield, P. R. Mechanisms of channel gating of the ligand-gated ion channel superfamily inferred from protein structure. Exp. Physiol. 2004, 89, 145-153.
100. Bouzat, C.; Gumilar, F.; Spitzmaul, G.; Wang, H. L.; Rayes, D.; Hansen, S. B.; Taylor, P.; Sine, S. M. Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel. Nature 2004, 430, 896-900.
101. A receptor. Nature 2003, 421, 272-275.
102. Absalom, N. L.; Lewis, T. M.; Kaplan, W.; Pierce, K. D.; Schofield, P. R. Role of charged residues in coupling ligand binding and channel activation in the extracellular domain of the glycine receptor. J. Biol. Chem. 2003, 278, 50151-50157.
103. 2+-binding sites. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 3210-3215.
104. Schapira, M.; Abagyan, R.; Totrov, M. Structural model of nicotinic acetylcholine receptor isotypes bound to acetylcholine and nicotine. BMC Struct. Biol. 2002, 2, 1.
105. Costa, V.; Nistri, A.; Cavalli, A.; Carloni, P. A structural model of agonist binding to the α3β4 neuronal nicotinic receptor. Br. J. Pharmacol. 2003, 140, 921-931.
106. Wang, H. L.; Gao, F.; Bren, N.; Sine, S. M. Curariform antagonists bind in different orientations to the nicotinic receptor ligand binding domain. J. Biol. Chem. 2003, 278, 32284-32291.
107. A receptor structure relieved by AChBP. Trends Biochem. Sci. 2002, 27, 280-287.
108. Nevin, S. T.; Cromer, B. A.; Haddrill, J. L.; Morton, C. J.; Parker, M. W.; Lynch, J. W. Insights into the structural basis for zinc inhibition of the glycine receptor. J. Biol. Chem. 2003, 278, 28985-28992.
109. Gao, F.; Bern, N.; Little, A.; Wang, H. L.; Hansen, S. B.; Talley, T. T.; Taylor, P.; Sine, S. M. Curariform antagonists bind in different orientations to acetylcholine-binding protein. J. Biol. Chem. 2003, 278, 23020-23026.
110. Fruchart-Gaillard, C.; Gilquin, B.; Antil-Delbeke, S.; Le Novere, N.; Tamiya, T.; Corringer, P. J.; Changeux, J. P.; Menez, A.; Servent, D. Experimentally based model of a complex between a snake toxin and the α7 nicotinic receptor. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 3216-3221.
111. Harel, M.; Kasher, R.; Nicolas, A.; Guss, J. M.; Balass, M.; Fridkin, M.; Smit, A. B.; Brejc, K.; Sixma, T. K.; Katchalski-Katzir, E.; Sussman, J. L.; Fuchs, S. The binding site of acetylcholine receptor as visualized in the X-ray structure of a complex between α-bungarotoxin and a mimotope peptide. Neuron 2001, 32, 265-275.
112. Galzi, J. L.; Bertrand, S.; Corringer, P. J.; Changeux, J. P.; Bertrand, D. Identification of calcium binding sites that regulate potentiation of a neuronal nicotinic acetylcholine receptor. EMBO J. 1996, 15, 5824-5832.
113. Mayer, M. L.; Armstrong, N. Structure and function of glutamate receptor ion channels. Annu. Rev. Physiol. 2004, 66, 161-181.
114. Jensen, A. A. Molecular pharmacology of the metabotropic glutamate receptors. In Molecular Neuropharmacology. Strategies and Methods; Schousboe, A., Bräuner-Osborne, H., Eds.; Humana Press: Totowa, NJ, 2004; pp 47-82.
115. Tikhonov, D. B.; Mellor, I. R.; Usherwood, P. N. Modeling noncompetitive antagonism of a nicotinic acetylcholine receptor. Biophys. J. 2004, 87, 159-170.
116. Romanelli, M. N.; Gualtieri, F. Cholinergic nicotinic receptors: Competitive ligands, allosteric modulators, and their potential applications. Med. Res. Rev. 2003, 23, 393-426.
117. Bunnelle, W. H.; Dart, M. J.; Schrimpf, M. R. Design of ligands for the nicotinic acetylcholine receptors: The quest for selectivity. Curr. Top. Med. Chem. 2004, 4, 299-334.
118. Abreo, M. A.; Lin, N. H.; Garvey, D. S.; Gunn, D. E.; Hettinger, A. M.; Wasicak, J. T.; Pavlik, P. A.; Martin, Y. C.; Donnelly-Roberts, D. L.; Anderson, D. J.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1996, 39, 817-825.
119. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Piattoni-Kaplan, M.; Campbell, J. E.; McKenna, D. G.; Molinari, E.; Hettinger, A. M.; Garvey, D. S.; Wasicak, J. T.; Holladay, M. W.; Williams, M.; Arneric, S. P. A-85380 [3-(2(S)-azetidinylmethoxy)pyridine]: in vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand. Neuropharmacology 1996, 35, 725-734.
120. Mukhin, A. G.; Gundisch, D.; Horti, A. G.; Koren, A. O.; Tamagnan, G.; Kimes, A. S.; Chambers, J.; Vaupel, D. B.; King, S. L.; Picciotto, M. R.; Innis, R. B.; London, E. D. 5-Iodo-A-85380, an α4β2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol. Pharmacol. 2000, 57, 642-649.
121. Xiao, Y.; Kellar, K. J. The comparative pharmacology and upregulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells. J. Pharmacol. Exp. Ther. 2004, 370, 98-107.
122. Kulak, J. M.; Sum, J.; Musachio, J. L.; McIntosh, J. M.; Quik, M. 5-Iodo-A-85380 binds to α-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as α4β2* subtypes. J. Neurochem. 2002, 81, 403-406.
123. Holladay, M. W.; Wasicak, J. T.; Lin, N. H.; He, Y.; Ryther, K. B.; Bannon, A. W.; Buckley, M. J.; Kim, D. J.; Decker, M. W.; Anderson, D. J.; Campbell, J. E.; Kuntzweiler, T. A.; Donnelly-Roberts, D. L.; Piattoni-Kaplan, M.; Briggs, C. A.; Williams, M.; Arneric, S. P. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1998, 41, 407-412.
124. Donnelly-Roberts, D. L.; Puttfarcken, P. S.; Kuntzweiler, T. A.; Briggs, C. A.; Anderson, D. J.; Campbell, J. E.; Piattoni-Kaplan, M.; McKenna, D. G.; Wasicak, J. T.; Holladay, M. W.; Williams, M.; Arneric, S. P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. J. Pharmacol. Exp. Ther. 1998, 285, 777-786.
125. Bannon, A. W.; Decker, M. W.; Curzon, P.; Buckley, M. J.; Kim, D. J.; Radek, R. J.; Lynch, J. K.; Wasicak, J. T.; Lin, N. H.; Arnold, W. H.; Holladay, M. W.; Williams, M.; Arneric, S. P. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2- chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J. Pharmacol. Exp. Ther. 1998, 285, 787-794.
126. Bannon, A. W.; Decker, M. W.; Holladay, M. W.; Curzon, P.; Donnelly-Roberts, D.; Puttfarcken, P. S.; Bitner, R. S.; Diaz, A.; Dickenson, A. H.; Porsolt, R. D.; Williams, M.; Arneric, S. P. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998, 279, 77-81.
127. Badio, B.; Daly, J. W. Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 1994, 45, 563-569.
128. Lin, N. H.; Gunn, D. E.; Ryther, K. B.; Garvey, D. S.; Donnelly-Roberts, D. L.; Decker, M. W.; Brioni, J. D.; Buckley, M. J.; Rodrigues, A. D.; Marsh, K. G.; Anderson, D. J.; Buccafusco, J. J.; Prendergast, M. A.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J. Med. Chem. 1997, 40, 385-390.
129. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Xue, I. C.; Piattoni-Kaplan, M.; Molinari, E.; Campbell, J. E.; McKenna, D. G.; Gunn, D. E.; Lin, N. H.; Ryther, K. B.; He, Y.; Holladay, M. W.; Wonnacott, S.; Williams, M.; Arneric, S. P. ABT-089 [2-methyl-3-(2-(S)- pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J. Pharmacol. Exp. Ther. 1997, 283, 235-246.
130. Decker, M. W.; Bannon, A. W.; Curzon, P.; Gunther, K. L.; Brioni, J. D.; Holladay, M. W.; Lin, N. H.; Li, Y.; Daanen, J. F.; Buccafusco, J. J.; Prendergast, M. A.; Jackson, W. J.; Arneric, S. P. ABT-089 [2-methyl-3-(2-(S)- pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J. Pharmacol. Exp. Ther. 1997, 283, 247-258.
131. Rueter, L. E.; Anderson, D. J.; Briggs, C. A.; Donnelly-Roberts, D. L.; Gintant, G. A.; Gopalakrishnan, M.; Lin, N. H.; Osinski, M. A.; Reinhart, G. A.; Buckley, M. J.; Martin, R. L.; McDermott, J. S.; Preusser, L. C.; Seifert, T. R.; Su, Z.; Cox, B. F.; Decker, M. W.; Sullivan, J. P. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev. 2004, 10, 167-182.
132. Papke, R. L.; Thinschmidt, J. S.; Moulton, B. A.; Meyer, E. M.; Poirier, A. Activation and inhibition of rat neuronal nicotinic receptors by ABT-418. Br. J. Pharmacol. 1997, 120, 429-438.
133. Arneric, S. P.; Sullivan, J. P.; Briggs, C. A.; Donnelly-Roberts, D.; Anderson, D. J.; Raszkiewicz, J. L.; Hughes, M. L.; Cadman, E. D.; Adams, P.; Garvey, D. S. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J. Pharmacol. Exp. Ther. 1994, 270, 310-318.
134. Decker, M. W.; Brioni, J. D.; Sullivan, J. P.; Buckley, M. J.; Radek, R. J.; Raszkiewicz, J. L.; Kang, C. H.; Kim, D. J.; Giardina, W. J.; Wasicak, J. T. (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J. Pharmacol. Exp. Ther. 1994, 270, 319-328.
135. Brioni, J. D.; O'Neill, A. B.; Kim, D. J.; Buckley, M. J.; Decker, M. W.; Arneric, S. P. Anxiolytic-like effects of the novel cholinergic channel activator ABT-418. J. Pharmacol. Exp. Ther. 1994, 271, 353-361.
136. Cosford, N. D.; Bleicher, L.; Herbaut, A.; McCallum, J. S.; Vernier, J. M.; Dawson, H.; Whitten, J. P.; Adams, P.; Chavez-Noriega, L.; Correa, L. D.; Crona, J. H.; Mahaffy, L. S.; Menzaghi, F.; Rao, T. S.; Reid, R.; Sacaan, A. I.; Santori, E.; Stauderman, K. A.; Whelan, K.; Lloyd, G. K.; McDonald, I. A. (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidmyl)pyridine maleate (SIB-1508Y): a novel anti-Parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1996, 39, 3235-3237.
137. Cosford, N. D.; Bleicher, L.; Vernier, J. M.; Chavez-Noriega, L.; Rao, T. S.; Siegel, R. S.; Suto, C.; Washburn, M.; Lloyd, G. K.; McDonald, I. A. Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist. Pharm. Acta Helv. 2000, 74, 125-130.
138. Sacaan, A. I.; Reid, R. T.; Santori, E. M.; Adams, P.; Correa, L. D.; Mahaffy, L. S.; Bleicher, L.; Cosford, N. D.; Stauderman, K. A.; McDonald, I.
139. Menzaghi, F.; Whelan, K. T.; Risbrough, V. B.; Rao, T. S.; Lloyd, G. K. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J. Pharmacol. Exp. Ther. 1997, 280, 393-401.
140. Schneider, J. S.; Tinker, J. P.; Van Velson, M.; Menzaghi, F.; Lloyd, G. K. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J. Pharmacol. Exp. Ther. 1999, 290, 731-739.
141. Vernier, J. M.; El-Abdellaoui, H.; Holsenback, H.; Cosford, N. D.; Bleicher, L.; Barker, G.; Bontempi, B.; Chavez-Noriega, L.; Menzaghi, F.; Rao, T. S.; Reid, R.; Sacaan, A. I.; Suto, C.; Washburn, M.; Lloyd, G. K.; McDonald, I. A. 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1999, 42, 1684-1686.
142. Rao, T. S.; Reid, R. T.; Correa, L. D.; Santori, E. M.; Gardner, M. F.; Sacaan, A. I.; Lorrain, D.; Vernier, J. M. In vivo pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thiophenol hydrochloride (SIB-1553A), a novel cholinergic ligand: microdialysis studies. Brain Res. 2003, 986, 71-81.
143. Schneider, J. S.; Tinker, J. P.; Menzaghi, F.; Lloyd, G. K. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Ther. 2003, 306, 401-406.
144. Bontempi, B.; Whelan, K. T.; Risbrough, V. B.; Lloyd, G. K.; Menzaghi, F. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology 2003, 28, 1235-1246.
145. Bontempi, B.; Whelan, K. T.; Risbrough, V. B.; Rao, T. S.; Buccafusco, J. J.; Lloyd, G. K.; Menzaghi, F. SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl) ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates. J. Pharmacol. Exp. Ther. 2001, 299, 297-306.
146. Vernier, J. M.; Holsenback, H.; Cosford, N. D.; Whitten, J. P.; Menzaghi, F.; Reid, R.; Rao, T. S.; Sacaan, A. I.; Lloyd, G. K.; Suto, C. M.; Chavez-Noriega, L. E.; Washburn, M. S.; Urrutia, A.; McDonald, I. A. Conformationally restricted analogues of nicotine and anabasine. Bioorg. Med. Chem. Lett. 1998, 8, 2173-2178.
147. Rao, T. S.; Sacaan, A. I.; Menzaghi, F. M.; Reid, R. T.; Adams, P. B.; Correa, L. D.; Whelan, K. T.; Vernier, J. M. Pharmacological characterization of SIB-1663, a conformationally rigid analog of nicotine. Brain Res. 2004, 1003, 42-53.
148. Bencherif, M.; Lovette, M. E.; Fowler, K. W.; Arrington, S.; Reeves, L.; Caldwell, W. S.; Lippiello, P. M. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. J. Pharmacol. Exp. Ther. 1996, 279, 1413-1421.
149. Papke, R. L.; Webster, J. C.; Lippiello, P. M.; Bencherif, M.; Francis, M. M. The activation and inhibition of human nicotinic acetylcholine receptor by RJR-2403 indicate a selectivity for the α4β2 receptor subtype. J. Neurochem. 2000, 75, 204-216.
150. Summers, K. L.; Lippiello, P.; Giacobini, E. A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines. Neurochem. Res. 1996, 21, 1181-1186.
151. Damaj, M. I.; Glassco, W.; Aceto, M. D.; Martin, B. R. Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist. J. Pharmacol. Exp. Ther. 1999, 291, 390-398.
152. Bencherif, M.; Bane, A. J.; Miller, C. H.; Dull, G. M.; Gatto, G. J. TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors. Eur. J. Pharmacol. 2000, 409, 45-55.
153. Chen, Y.; Sharples, T. J.; Phillips, K. G.; Benedetti, G.; Broad, L. M.; Zwart, R.; Sher, E. The nicotinic α4β2 receptor selective agonist, TC-2559, increases dopamine neuronal activity in the ventral tegmental area of rat midbrain slices. Neuropharmacology 2003, 45, 334-344.
154. Lippiello, P. M.; Bencherif, M.; Gray, J. A.; Peters, S.; Grigoryan, G.; Hodges, H.; Collins, A. C. RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization. J. Pharmacol. Exp. Ther. 1996, 279, 1422-1429
155. Gatto, G. J.; Bohme, G. A.; Caldwell, W. S.; Letchworth, S. R.; Traina, V. M.; Obinu, M. C.; Laville, M.; Reibaud, M.; Pradier, L.; Dunbar, G.; Bencherif, M. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev. 2004, 10, 147-166.
156. Bohme, G. A.; Letchworth, S. R.; Piot-Grosjean, O.; Gatto, G. J.; Obinu, M. C.; Caldwell, W. S.; Laville, M.; Brunei, P.; Pellerin, R.; Leconte, J. P.; Genevois-Borella, A.; Dubedat, P.; Mazadier, M.; Pradier, L.; Bencherif, M.; Benavides, J. In vitro and in vivo characteristics of TC-1827, a novel brain α4β2 nicotinic receptor agonist with pro-cognitive activity. Drug Dev. Res. 2004, 62, 26-40.
157. Obinu, M. C.; Reibaud, M.; Miquet, J. M.; Pasquet, M.; Rooney, T. Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26, 913-918.
158. Bencherif, M.; Schmitt, J. D.; Bhatti, B. S.; Crooks, P.; Caldwell, W. S.; Lovette, M. E.; Fowler, K.; Reeves, L.; Lippiello, P. M. The heterocyclic substituted pyridine derivative (+/-)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 1998, 284, 886-894.
159. Cohen, C.; Bergis, O. E.; Galli, F.; Lochead, A. W.; Jegham, S.; Biton, B.; Leonardon, J.; Avenet, P.; Sgard, F.; Besnard, F.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Voltz, C.; Gardes, A.; Caille, D.; Perrault, G.; George, P.; Soubrie, P.; Scatton, B. SSR591813, a novel selective and partial α4β2 nicotinic receptor agonist with potential as an aid to smoking cessation. J. Pharmacol. Exp. Ther. 2003, 306, 407-420.
160. Efange, S. M.; Tu, Z.; von Hohenberg, K.; Francesconi, L.; Howell, R. C.; Rampersad, M. V.; Todaro, L. J.; Papke, R. L.; Kung, M. P. 2-(2-Piperidyl)- and 2-(2-pyrrolidyl)chromans as nicotine agonists: synthesis and preliminary pharmacological characterization. J. Med. Chem. 2001, 44, 4704-4715.
161. Astles, P. C.; Baker, S. R.; Boot, J. R.; Broadmore, R.; Dell, C. P.; Dehlinger, V.; Dreyfus, N.; Keenan, M.; O'Connor, E. A.; Sanderson, A. J.; Smith, C. W.; Waterhouse, N. Synthesis and SAR of (biarylthio)tropanes: potent, selective agonists at the nicotinic acetylcholine β4 receptor subtype. Part II. Variation of the cation, linker and proximal aromatic regions. Presented at the XVIIIth International Symposium on Medicinal Chemistry, Copenhagen, Denmark 2004; Poster 244.
162. Astles, P. C.; Baker, S. R.; Boot, J. R.; Broadmore, R.; Dell, C. P.; Dehlinger, V.; Dreyfus, N.; Goldsworthy, J.; Keenan, M.; Sanderson, A. J.; Waterhouse, N. Synthesis and SAR of (biarylthio)tropanes: potent, selective agonists at the nicotinic acetylcholine β4 receptor subtype. Part I. Variation of the distal aromatic. Presented at the XVIIIth International Symposium on Medicinal Chemistry, Copenhagen, Denmark, 2004; Poster 243.
163. Carroll, F. I.; Liang, F.; Navarro, H. A.; Brieaddy, L. E.; Abraham, P.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′-substituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Epibatidine analogues. J. Med. Chem. 2001, 44, 2229-2237.
164. Avalos, M.; Parker, M. J.; Maddox, F. N.; Carroll, F. I.; Luetje, C. W. Effects of pyridine ring substitutions on affinity, efficacy, and subtype selectivity of neuronal nicotinic receptor agonist epibatidine. J. Pharmacol. Exp. Ther. 2002, 302, 1246-1252.
165. Che, D.; Wegge, T.; Stubbs, M. T.; Seitz, G.; Meier, H.; Methfessel, C. exo-2-(Pyridazin-4-yl)-7-azabicyclo[2.2.1]heptanes: syntheses and nicotinic acetylcholine receptor agonist activity of potent pyridazine analogues of (+/-)-epibatidine. J. Med. Chem. 2001, 44, 47-57.
166. Jensen, A. A.; Mikkelsen, I.; Frølund, B.; Bräuner-Osborne, H.; Falch, E.; Krogsgaard-Larsen, P. Carbamoylcholine homologs: Novel and potent agonists at neuronal nicotinic acetylcholine receptors. Mol. Pharmacol. 2003, 64, 865-875.
167. Jensen, A. A.; Mikkelsen, I.; Frolund, B.; Frydenvang, K.; Brehm, L.; Jaroszewski, J. W.; Bräuner-Osborne, H.; Falch, E.; Krogsgaard-Larsen, P. Carbamoylcholine homologs: Synthesis and pharmacology at nicotinic acetylcholine receptors. Eur. J. Pharmacol. 2004, 497, 125-137.
168. Slater, Y. E.; Houlihan, L. M.; Maskell, P. D.; Exley, R.; Bermudez, I.; Lukas, R. J.; Valdivia, A. C.; Cassels, B. K. Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology 2003, 44, 513-523.
169. Carbonnelle, E.; Sparatore, F.; Canu-Boido, C.; Salvagno, C.; Baldani-Guerra, B.; Terstappen, G.; Zwart, R.; Vijverberg, H.; Clementi, F.; Gotti, C. Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes. Eur. J. Pharmacol. 2003, 471, 85-96.
170. 125I-alpha-bungarotoxin receptor subtypes. Mol. Pharmacol. 1995, 47, 164-171.
171. Kem, W. R.; Mahnir, V. M.; Papke, R. L.; Lingle, C. J. Anabaseine is a potent agonist on muscle and neuronal α-bungarotoxin-sensitive nicotinic receptors. J. Pharmacol. Exp. Ther. 1997, 283, 979-992.
172. Astles, P. C.; Baker, S. R.; Boot, J. R.; Broad, L. M.; Dell, C. P.; Keenan, M. Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr. Drug Targets: CNS Neuro. Disord. 2002, 1, 337-348.
173. Meyer, E. M.; Kuryatov, A.; Gerzanich, V.; Lindstrom, J.; Papke, R. L. Analysis of 3-(4-hydroxy, 2-methoxybenzylidene)anabaseine selectivity and activity at human and rat α7 nicotinic receptors. J. Pharmacol. Exp. Ther. 1998, 287, 918-925.
174. Stokes, C.; Papke, J. K.; Horenstein, N. A.; Kem, W. R.; McCormack, T. J.; Papke, R. L. The structural basis for GTS-21 selectivity between human and rat nicotinic α7 receptors. Mol. Pharmacol. 2004, 66, 14-24.
175. Kem, W. R.; Mahnir, V. M.; Prokai, L.; Papke, R. L.; Cao, X.; LeFrancois, S.; Wildeboer, K.; Prokai-Tatrai, K.; Porter-Papke, J.; Soti, F. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]- anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol. Pharmacol. 2004, 65, 56-67.
176. 3A receptor. J. Pharmacol. Exp. Ther. 2001, 299, 1112-1119.
177. Mullen, G.; Napier, J.; Balestra, M.; DeCory, T.; Hale, G.; Macor, J.; Mack, R.; Loch, J., 3rd; Wu, E.; Kover, A.; Verhoest, P.; Sampognaro, A.; Phillips, E.; Zhu, Y.; Murray, R.; Griffith, R.; Blosser, J.; Gurley, D.; Machulskis, A.; Zongrone, J.; Rosen, A.; Gordon, J. (-)-Spiro[1-azabicyclo[2.2. 2]octane-3,5′-oxazolidin-2′-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the α7 nicotinic acetylcholine receptor. J. Med. Chem. 2000, 43, 4045-4050.
178. 3 receptors expressed in Xenopus oocytes. Bioorg. Med. Chem. Lett. 2004, 14, 1849-1853.
179. 3 receptor. Eur. J. Pharmacol. 2002, 452, 137-144.
180. Bodnar, A. L.; Cortes-Burgos, L. A.; Cook, K. K.; Dinh, D. M.; Groppi, V. E.; Hajos, M.; Higdon, N. R.; Hoffmann, W. E.; Hurst, R. S.; Myers, J. K.; Rogers, B. N.; Wall, T. M.; Wolfe, M. L.; Wong, E. The discovery and structure-activity relationships of quinuclidine benzamides as agonists of α7 nicotinic acetylcholine receptors (nAChRs). J. Med. Chem. 2005, 48, 905-908.
181. De Filippi, H.; Broad, L. M.; Zwart, R.; Baldwinson, T.; Felthouse, C.; McPhie, G.; Pearson, K.; Craig, P. J.; Broadmore, R.; Bell, E.; Cases, M.; Keenan, M.; Baker, S. R.; Boot, J.; Sher, E. Pharmacological characterization and in vitro physiological effects of new α7 nicotinic acetylcholine receptor agonists. Soc. Neurosci. Abstr. 2002, 137, 5.
182. Wishka, D. G.; Reitz, S. C.; Piotrowski, D. W.; Groppi, V. E., Jr. Preparation and formulation of N-quinuclidinyl-heteroaryls as nicotinic acetylcholinergic receptor modulators for the treatment of a variety of central nervous system disorders. PCT Int. Appl. WO 0100857, 2002.
183. Marrero, M. B.; Papke, R. L.; Bhatti, B. S.; Shaw, S.; Bencherif, M. The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]-nonane (TC-1698), a novel α7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. J. Pharmacol. Exp. Ther. 2004, 309, 16-27.
184. Alkondon, M.; Pereira, E. F.; Cortes, W. S.; Maelicke, A.; Albuquerque, E. X. Choline is a selective agonist of α7 nicotinic acetylcholine receptors in the rat brain neurons. Eur. J. Neurosci. 1997, 9, 2734-2742.
185. Briggs, C. A.; McKenna, D. G.; Monteggia, L. M.; Tourna, E.; Roch, J. M.; Arneric, S. P.; Gopalakrishnan, M.; Sullivan, J. P. Gain of function mutation of the α7 nicotinic receptor: distinct pharmacology of the human α7V274T variant. Eur. J. Pharmacol. 1999, 366, 301-308.
186. 3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist. Bioorg. Med. Chem. Lett. 2001, 11, 319-321.
187. O'Neill, M. J.; Moore, N. A.; McKinzie, D. L.; Keenan, M.; Wishart, G.; O'Neill, M. F.; Shannon, H. E.; Murray, T. K.; Tree, B.; Iyengar, S.; Hart, J.; Shaw, D.; Simmons, R.; Kalra, A. B.; Miles, C.; Baker, S. R.; Sher, E.; Tricklebank, M. D. Behavioral profiling of two potent α7 nicotinic acetylcholine receptor agonists. Soc. Neurosci. Abstr. 2002, 137, 6.
188. Levin, E. D.; Bettegowda, C.; Blosser, J.; Gordon, J. AR-R17779, an α7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol. 1999, 10, 675-680.
189. Grottick, A. J.; Higgins, G. A. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav. Brain Res. 2000, 117, 197-208.
190. Schreiber, R.; Dalmus, M.; De Vry, J. Effects of α4/β2- and α7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology 2002, 159, 248-257.
191. Hahn, B.; Sharples, C. G.; Wonnacott, S.; Shoaib, M.; Stolerman, I. P. Attentional effects of nicotinic agonists in rats. Neuropharmacology 2003, 44, 1054-1067.
192. Van Kampen, M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors. Psychopharmacology 2004, 172, 375-383.
193. Briggs, C. A.; McKenna, D. G. Activation and inhibition of the human α7 nicotinic acetylcholine receptor by agonists. Neuropharmacology 1998, 37, 1095-1102.
194. Kem, W. R. The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav. Brain Res. 2000, 113, 169-181.
195. Stevens, K. E.; Kem, W. R.; Mahnir, V. M.; Freedman, R. Selective α7-nicotinic agonists normalise inhibition of auditory response in DBA mice. Pnychopharmacology 1998, 136, 320-327.
196. O'Neill, H. C.; Rieger, K.; Kem, W. R.; Stevens, K. E. DMXB, an α7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology 2003, 169, 332-339.
197. Hajos, M.; Hurst, R. S.; Hoffmann, W. E.; Krause, M.; Wall, T. M.; Higdon, N. R.; Groppi, V. E. The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther. 2005, 312, 1213-1222.
198. Wilkins, L. H., Jr.; Grinevich, V. P.; Ayers, J. T.; Crooks, P. A.; Dwoskin, L. P. N-n-Alkylnicotinium analogues, a novel class of nicotinic receptor antagonists: interaction with α4β2* and α7* neuronal nicotinic receptors. J. Pharmacol. Exp. Ther. 2003, 304, 400-410.
199. 3H]dopamine overflow from superfused rat striatal slices. J. Pharmacol. Exp. Ther. 2002, 307, 1088-1096.
200. Crooks, P. A.; Ayers, J. T.; Xu, R.; Sumithran, S. P.; Grinevich, V. P.; Wilkins, L. H.; Deaciuc, A. G.; Allen, D. D.; Dwoskin, L. P. Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg. Med. Chem. Lett. 2004, 14, 1869-1874.
201. Itier, V.; Schonbachler, R.; Tribollet, E.; Honer, M.; Prinz, K.; Marguerat, A.; Bertrand, S.; Bunnelle, W. H.; Schubiger, P. A.; Meyer, M. D.; Sullivan, J. P.; Bertrand, D.; Westera, G. A-186253, a specific antagonist of the α4β2 nAChRs: its properties and potential to study brain nicotinic acetylcholine receptors. Neuropharmacology 2004, 47, 538-557.
202. Carroll, F. I.; Lee, J. R.; Navarro, H. A.; Brieaddy, L. E.; Abraham, P.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′-substituted- 3′-phenyl-5′-pyridinyl)-7-azabicyclo-[2.2.1]heptane s. Novel nicotinic antagonist. J. Med. Chem. 2001, 44, 4039-4041.
203. Carroll, F. I.; Lee, J. R.; Navarro, H. A.; Ma, W.; Brieaddy, L. E.; Abraham, P.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′,3′- disubstituted 5′-pyridinyl)-7-azabicyclo[2.2.1]-heptanes: epibatidine analogues. J. Med. Chem. 2002, 45, 4755-4761.
204. Carroll, F. I.; Ware, R.; Brieaddy, L. E.; Navarro, H. A.; Damaj, M. I.; Martin, B. R. Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2′-fluoro-3′-(substituted phenyl)deschloroepibatidine analogues. Novel nicotinic antagonist. J. Med. Chem. 2004, 47, 4588-4594.
205. Maggi, L.; Palma, E.; Eusebi, F.; Moretti, M.; Balestra, B.; Clementi, F.; Gotti, C. Selective effects of a 4-oxystilbene derivative on wild and mutant neuronal chick α7 nicotinic receptor. Br. J. Pharmacol. 1999, 126, 285-295.
206. Di Angelantonio, S.; Nistri, A.; Moretti, M.; Clementi, F.; Gotti, C. Antagonism of nicotinic receptors of rat chromaffin cells by N,N,N-trimethyl-1-(4-trans-stilbenoxy)-2-propylammonium iodide: a patch clamp and ligand binding study. Br. J. Pharmacol. 2000, 129, 1771-1779.
207. Hardick, D. J.; Blagbrough, I. S.; Cooper, G.; Potter, B. V.; Critchley, T.; Wonnacott, S. Nudicauline and elatine as potent norditerpenoid ligands at rat neuronal α-bungarotoxin binding sites: importance of the 2-(methylsuccinimido)benzoyl moiety for neuronal nicotinic acetylcholine receptor binding. J. Med. Chem. 1996, 39, 4860-4866.
208. Bryant, D. L.; Free, R. B.; Thomasy, S. M.; Lapinsky, D. J.; Ismail, K. A.; McKay, S. B.; Bergmeier, S. C.; McKay, D. B. Structure-activity studies with ring E analogues of methyllycaconitine on bovine adrenal α3β4* nicotinic receptors. Neurosci. Res. 2002, 42, 57-63.
209. Bergmeier, S. C.; Ismail, K. A.; Arason, K. M.; McKay, S.; Bryant, D. L.; McKay, D. B. Structure activity studies of ring E analogues of methyllycaconitine. Part 2: Synthesis of antagonists to the α3β4 * nicotinic acetylcholine receptors through modifications to the ester. Bioorg. Med. Chem. Lett. 2004, 14, 3739-3742.
210. Olivera, B. M.; Rivier, J.; Clark, C.; Ramilo, C. A.; Corpuz, G. P.; Abogadie, F. C.; Mena, E. E.; Woodward, S. R.; Hillyard, D. R.; Cruz, L. J. Diversity of Conus neuropeptides. Science 1990, 249, 257-263.
211. McIntosh, J. M.; Santos, A. D.; Olivera, B. M. Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes. Annu. Rev. Biochem. 1999, 68, 59-88.
212. Nicke, A.; Wonnacott, S.; Lewis, R. J. α-Conotoxins as tools for the elucidation of structure and function of neuronal nicotinic acetylcholine receptor subtypes. Eur. J. Biochem. 2004, 271, 2305-2319.
213. McIntosh, J. M.; Yoshikami, D.; Mahe, E.; Nielsen, D. B.; Rivier, J. E.; Gray, W. R.; Olivera, B. M. A nicotinic acetylcholine receptor ligand of unique specificity, α-conotoxin ImI. J. Biol. Chem. 1994, 269, 16733-16739.
214. Ellison, M.; McIntosh, J. M.; Olivera, B. M. α-Conotoxins ImI and ImII. Similar α7 nicotinic receptor antagonists act at different sites. J. Biol. Chem. 2003, 278, 757-764.
215. Cartier, G. E.; Yoshikami, D.; Gray, W. R.; Luo, S.; Olivera, B. M.; McIntosh, J. M. A new α-conotoxin which targets α3β2 nicotinic acetylcholine receptors. J. Biol. Chem. 1996, 271, 7522-7528.
216. Loughnan, M.; Nicke, A.; Jones, A.; Adams, D. J.; Alewood, P. F.; Lewis, R. J. Chemical and functional identification and characterization of novel sulfated α-conotoxins from the cone snail Conus anemone. J. Med. Chem. 2004, 47, 1234-1241.
217. McIntosh, J. M.; Dowell, C.; Watkins, M.; Garrett, J. E.; Yoshikami, D.; Olivera, B. M. α-Conotoxin GIC from Conus geographus, a novel peptide antagonist of nicotinic acetylcholine receptors. J. Biol. Chem. 2002, 271, 33610-33615.
218. Nicke, A.; Loughnan, M. L.; Millard, E. L.; Alewood, P. F.; Adams, D. J.; Daly, N. L.; Craik, D. J.; Lewis, R. J. Isolation, structure, and activity of GID, a novel α4/7-conotoxin with an extended N-terminal sequence. J. Biol. Chem. 2003, 278, 3137-3144.
219. Azam, L.; Dowell, C.; Watkins, M.; Stitzel, J. A.; Olivera, B. M.; McIntosh, J. M. α-Conotoxin BuIA, a novel peptide from Conus bullatus distinguishes among neuronal nicotinic acetylcholine receptors. J. Biol. Chem. 2005, 280, 80-87,
220. Millard, E. L.; Daly, N. L.; Craik, D. J. Structure-activity relationships of α-conotoxins targeting neuronal nicotinic acetylcholine receptors. Eur. J. Biochem. 2004, 271, 2320-2326.
221. Olivera, B. M. E. E. Just Lecture, 1996. Conus venom peptides, receptor and ion channel targets, and drug design: 50 million years of neuropharmacology. Mol. Biol. Cell 1997, 8, 2101-2109.
222. Quiram, P. A.; Sine, S. M. Identification of residues in the neuronal α7 acetylcholine receptor that confer selectivity for conotoxin ImI. J. Biol. Chem. 1998, 273, 11001-11006.
223. Quiram, P. A.; Jones, J. J.; Sine, S. M. Pairwise interactions between neuronal α7 acetylcholine receptors and α-conotoxin ImI. J. Biol. Chem. 1999, 274, 19517-19524.
224. Quiram, P. A.; McIntosh, J. M.; Sine, S. M. Pairwise interactions between neuronal α7 acetylcholine receptors and α-conotoxin PnIB. J. Biol. Chem. 2000, 275, 4889-4896.
225. Hogg, R. C.; Miranda, L. P.; Craik, D. J.; Lewis, R. J.; Alewood, P. F.; Adams, D. J. Single amino acid substitutions in α-conotoxin PnIA shift selectivity for subtypes of the mammalian neuronal nicotinic acetylcholine receptor. J. Biol. Chem. 1999, 274, 36559-36564.
226. Everhart, D.; Reiller, E.; Mirzoian, A.; McIntosh, J. M.; Malhotra, A.; Luetje, C. W. Identification of residues that confer α-conotoxin-PnIA sensitivity on the α3 subunit of neuronal nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 2003, 306, 664-670.
227. Harvey, S. C.; McIntosh, J. M.; Cartier, G. E.; Maddox, F. N.; Luetje, C. W. Determinants of specificity for alpha-conotoxin MII on α3β2 neuronal nicotinic receptors. Mol. Pharmacol. 1997, 51, 336-342.
228. Quiram, P. A.; Sine, S. M. Structural elements in α-conotoxin ImI essential for binding to neuronal α7 receptors. J. Biol. Chem. 1998, 273, 11007-11011,
229. Lamthanh, H.; Jegou-Matheron, C.; Servent, D.; Menez, A.; Lancelin, J. M. Minimal conformation of the α-conotoxin ImI for the α7 neuronal nicotinic acetylcholine receptor recognition: correlated CD, NMR and binding studies. FEES Lett, 1999, 454, 293-298.
230. Everhart, D.; Cartier, G. E.; Malhotra, A.; Gomes, A. V.; McIntosh, J. M.; Luetje, C. W. Determinants of potency on α-conotoxin MII, a peptide antagonist of neuronal nicotinic receptors. Biochemistry 2004, 43, 2732-2737,
231. Dutertre, S.; Nicke, A.; Tyndall, J. D.; Lewis, R. J. Determination of α-conotoxin binding modes on neuronal nicotinic acetylcholine receptors. J. Mol. Recognit. 2004, 17, 339-347,
232. Luo, S.; Nguyen, T. A.; Cartier, G. E.; Olivera, B. M.; Yoshikami, D.; McIntosh, J. M. Single-residue alteration in α-conotoxin PnIA switches its nAchR subtype selectivity. Biochemistry 1999, 38, 14542-14548.
233. McIntosh, J. M.; Azam, L.; Staheli, S.; Dowell, C.; Lindstrom, J. M.; Kuryatov, A.; Garrett, J. E.; Marks, M. J.; Whiteaker, P. Analogs of α-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors. Mol. Pharmacol. 2004, 65, 944-952.
234. Button, J. L.; Bansal, P. S.; Hogg, R. C.; Adams, D. J.; Alewood, P. F.; Craik, D. J. A new level of conotoxin diversity, a non-native disulfide bond connectivity in α-conotoxin AuIB reduces structural definition but increases biological activity. J. Biol. Chem. 2002, 277, 48849-48857,
235. Sandall, D. W.; Satkunanathan, N.; Keays, D. A.; Polidano, M. A.; Liping, X.; Pham, V.; Down, J. G.; Khalil, Z.; Livett, B. G.; Gayler, K. R. A novel α-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry 2003, 42, 6904-6911,
236. Arneric, S. P.; Holladay, M. W. Agonists and antagonists of nicotinic acetylcholine receptors. In Neuronal Nicotinic Receptors; Clementi, F., Fornasari, D., Gotti, C., Eds.; Handbook of Experimental Pharmacology, Vol. 144; Springer; Berlin, 2000; pp 419-453.
237. Pereira, E. F.; Hilmas, C.; Santos, M. D.; Alkondon, M.; Maelicke, A.; Albuquerque, E. X. Unconventional ligands and modulators of nicotinic receptors. J. Neurobiol. 2002, 53, 479-500.
238. Hsiao, B.; Dweck, D.; Luetje, C. W. Subunit-dependent modulation of neuronal nicotinic receptors by zinc. J. Neurosci. 2001, 21, 1848-1856.
239. 2+ on wild and mutant neuronal α7 nicotinic receptors. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10246-10250.
240. 1-42 binds to α7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 2000, 275, 5626-5632.
241. 1-42 binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors. J. Neurochem. 2000, 75, 1155-1161.
242. Dineley, K. T.; Bell, K. A.; Bui, D.; Sweatt, J. D. β-Amyloid peptide activates α7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Biol. Chem. 2002, 277, 25056-25061.
243. Liu, Q.; Kawai, H.; Berg, D. K. β-Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4734-4739,
244. 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci. 2001, 21, RC120.
245. Conroy, W. G.; Liu, Q. S.; Nai, Q.; Margiotta, J. F.; Berg, D. K. Potentiation of α7-containing nicotinic acetylcholine receptors by select albumins. Mol. Pharmacol. 2003, 63, 419-428.
246. Webster, J. C.; Francis, M. M.; Porter, J. K.; Robinson, G.; Stokes, C.; Horenstein, B.; Papke, R. L. Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain. Br. J. Pharmacol. 1999, 127, 1337-1348,
247. Young, J. M.; Shytle, R. D.; Sanberg, P. R.; George, T. P. Mecamylamine: new therapeutic uses and toxicity/risk profile. Clin. Ther. 2001, 23, 532-565.
248. Fryer, J. D.; Lukas, R. J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 1999, 288, 88-92.
249. Slemmer, J. E.; Martin, B. R.; Damaj, M. I. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 2000, 295, 321-327.
250. Damaj, M. I.; Carroll, F. I.; Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza, S.; Lukas, R. J.; Martin, B. R. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol. 2004, 66, 675-682.
251. Zwart, R.; De Filippi, G.; Broad, L. M.; McPhie, G. I.; Pearson, K. H.; Baldwinson, T.; Sher, E. 5-Hydroxyindole potentiates human α7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 2002, 43, 374-384.
252. van Hooft, J. A.; van der Haar, E.; Vijverberg, H. P. Allosteric potentiation of the 5-HTg receptor-mediated ion current in N1E-115 neuroblastoma cells by 5-hydroxyindole and analogues. Neuropharmacology 1997, 36, 649-653,
253. Pereira, E. F.; Reinhardt-Maelicke, S.; Schrattenholz, A.; Maelicke, A.; Albuquerque, E. X. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 1993, 265, 1474-1491.
254. Schrattenholz, A.; Pereira, E. F.; Roth, U.; Weber, K. H.; Albuquerque, E. X.; Maelicke, A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 1996, 49, 1-6.
255. 2+ signals and neurotransmitter release. Mol. Pharmacol. 2003, 64, 1217-1226.
256. Samochocki, M.; Hoffle, A.; Fehrenbacher, A.; Jostock, R.; Ludwig, J.; Christner, C.; Radina, M.; Zerlin, M.; Ullmer, C.; Pereira, E. F.; Lubbert, H.; Albuquerque, E. X.; Maelicke, A. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 2003, 305, 1024-1036.
257. Zhang, L.; Zhou, F. M.; Dani, J. A. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol. Pharmacol. 2004, 66, 538-544.
258. Hu, S. H.; Gehrmann, J.; Guddat, L. W.; Alewood, P. F.; Craik, D. J.; Martin, J. L. The 1.1 Å crystal structure of the neuronal acetylcholine receptor antagonist, α-conotoxin PnIA from Conus pennaceus. Structure 1996, 4, 417-423.
259. Shon, K. J.; Koerber, S. C.; Rivier, J. E.; Olivera, B. M.; McIntosh, J. M. Three-dimensional solution structure of α-conotoxin MII, an α3β2 neuronal nicotinic acetylcholine receptor-targeted ligand. Biochemistry 1997, 36, 15693-15700.
260. Rogers, J. P.; Luginbuhl, P.; Shen, G. S.; McCabe, R. T.; Stevens, R. C.; Wemmer, D. E. NMR solution structure of α-conotoxin ImI and comparison to other conotoxins specific for neuronal nicotinic acetylcholine receptors. Biochemistry 1999, 38, 3874-3882.
261. Cho, J. H.; Mok, K. H.; Olivera, B. M.; McIntosh, J. M.; Park, K. H.; Han, K. H. Nuclear magnetic resonance solution conformation of α-conotoxin AuIB, an α3β4 subtype-selective neuronal nicotinic acetylcholine receptor antagonist. J. Biol. Chem. 2000, 275, 8680-8685.
262. Rossi, F. M.; Pizzorusso, T.; Porciatti, V.; Marubio, L. M.; Maffei, L.; Changeux, J. P. Requirement of the nicotinic acetylcholine receptor β2 subunit for the anatomical and functional development of the visual system. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 6453-6458.
263. Marubio, L. M.; Gardier, A. M.; Durier, S.; David, D.; Klink, R.; Arroyo-Jimenez, M. M.; McIntosh, J. M.; Rossi, F.; Champtiaux, N.; Zoli, M.; Changeux, J. P. Effects of nicotine in the dopaminergic system of mice lacking the α4 subunit of neuronal nicotinic acetylcholine receptors. Eur. J. Neurosci. 2003, 17, 1329-1337.
264. Rao, T. S.; Adams, P. B.; Correa, L. D.; Santori, E. M.; Sacaan, A. I.; Reid, R. T.; Suto, C. M.; Vernier, J. M. In vitro pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)-ethyl]thio]phenol hydrochloride (SIB-1553A), a nicotinic acetylcholine receptor ligand. Brain Res. 2003, 981, 85-98.
265. Papke, R. L.; Porter Papke, J. K. Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis. Br. J. Pharmacol. 2002, 137, 49-61.
266. Johnson, D. S.; Martinez, J.; Elgoyhen, A. B.; Heinemann, S. F.; McIntosh, J. M. α-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric α7 and α9 receptors. J. Med. Chem. 1995, 48, 194-199.
267. Nicke, A.; Samochocki, M.; Loughnan, M. L.; Bansal, P. S.; Maelicke, A.; Lewis, R. J. α-Conotoxins EpI and AuIB switch subtype selectivity and activity in native versus recombinant nicotinic acetylcholine receptors. FEBS Lett. 2003, 554, 219-223.
268. Dutertre, S.; Lewis, R. J. Computational approaches to understand α-conotoxin interactions at neuronal nicotinic receptors. Eur. J. Biochem. 2004, 271, 2327-2334.